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ABSTRACT
Background: The presence of both myasthenia gravis (MG) and Lambert-Eaton myasthenic 
syndrome (LEMS) in one patient is very rare. Here, we report the case of a patient with these 
coexisting conditions. Case Presentstion: An 82-year-old man with a history of adenocarcinoma 
of the bladder was referred to the neurology ward with diplopia, dysphagia, ptosis in the left eye, 
weakness in both lower extremities, and autonomic dysfunction. Coexistence of MG and LEMS 
was diagnosed according to clinical and para-clinical evaluations. Conclusion: Coexistence of 
MG and LEMS is very rare, but this presentation in a patient with a history of adenocarcinoma 
of the bladder has not been previously reported. We emphasize the importance of carefully 
evaluating patients with LEMS for any underlying malignancy.
INTRODUCTION
Myasthenia gravis (MG) is a post-synaptic disorder, and 
Lambert-Eaton myasthenic syndrome (LEMS) is a pre-syn-
aptic disorder; both are well-known autoimmune neuro-
muscular junction disorders (1). LEMS is also a rare but 
well-known paraneoplastic disorder and is an autoimmune 
disorder that affects the neuromuscular junction. In 1956, 
Lambert and colleagues first reported six patients with atyp-
ical myasthenia and lung carcinoma. These patients had a 
specific response to repetitive nerve stimulation (RNS) that 
differed from the responses of patients with MG (2). Wirtz 
et al. reported a prevalence rate of 2.3 per million (annual 
incidence, 0.5 per million) for LEMS (3). In their study, this 
incidence rate was 1.4 times lower than MG. The mean age 
of these patients was 58 years. The syndrome is known to re-
late to a variety of malignancies, especially small-cell carci-
noma of the lung. Rare case reports in the literature reported 
the relationship between LEMS and bladder and ureter can-
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cers, especially transitional cell carcinoma of the bladder (4). 
Considering the underlying cause of the condition, it has a 
very poor prognosis (4) Coexistence of both MG and LEMS 
is very rare. Here, we report the case of an 82-year-old man 
with these coexisting conditions.
CASE PRESENTATION
The patient was an 82-year-old Jewish man with a history of 
adenocarcinoma of the bladder since about 11 months before 
admission to our center. He received several rounds of che-
motherapy. He was referred to the neurology clinic because 
of dysphagia, ptosis in the left eye, diplopia, autonomic 
dysfunction, and weakness in both lower extremities. In neu-
rological examinations, vital signs were within normal rang-
es, but orthostatic hypotension was present. Left eye ptosis 
was observed. In cranial nerve examination, gag reflex was 
impaired. In manual muscle strength testing, the power de-
creased to 4 out of 5 in both lower extremities. Deep tendon 
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reflexes were significantly decreased. Sensory examinations 
(light touch, pinprick) were normal, and Babinski’s signs 
were down-going bilaterally.
In laboratory tests, only a minimal elevation was ob-
served in blood urea nitrogen (35 mg/dl) and creatinine 
(2.1 mg/dl); other lab results were within normal ranges. 
Serum titer of antibodies against AChRs was significantly 
elevated (7.8 nmol/L; normal level, <0.1 nmol/L).
Brain magnetic resonance imaging showed meningio-
ma in the frontal lobe. Chest computed tomography did not 
show any sign of malignancy in the lung and was negative 
for thymoma. The edrophonium test (Tensilon test) showed 
significant clinical improvement of the left-eye ptosis. Elec-
tromyography and nerve conduction studies were normal. 
RNS with high frequency stimulation (30 Hz) showed a 
significant increase (400%) in increment in two samples. 
The patient’s symptoms gradually improved after treatment 
with both prednisolone (20 mg per day) and pyridostigmine 
(240 mg per day). Considering the patient’s history, physical 
examination, and para-clinical evaluations, coexisting MG 
and LEMS was diagnosed.
DISCUSSION
Typical patients with LEMS have a triad of proximal muscle 
weaknesses, areflexia, and autonomic dysfunction (4). RNS 
shows greater-than-100% incremental changes on high-rate 
stimulation. In most cases, a para-neoplastic origin from 
small-cell carcinoma of the lung is present (4,5). Conversely, 
oculobulbar symptoms, elevated anti-AChR antibody titers, 
and a positive edrophonium test are typical presentations of 
MG (5). The patient we report here had a unique profile. Oc-
ulobulbar symptoms, elevated anti-AChR antibody titers, a 
positive edrophonium test, and significant response to treat-
ment favored a diagnosis of MG.
However, presence of areflexia, abnormal electrophysi-
ological findings, and underlying malignancy favored a di-
agnosis of LEMS. Considering these facts, the coexistence 
in our patient of MG and LEMS, although very rare, was 
possible. In 1987, Oh et al. first identified what they termed 
overlap myasthenic syndrome (6). They used this term to de-
scribe a patient with combined MG and LEMS (6). In 1988, 
Taphoorn et al. reported another patient with coexistence of 
both diseases (7).
In 2012, Kim et al. reported the case of a 48-year-old 
woman with combined MG and LEMS, which was diag-
nosed according to her clinical and electrophysiological fea-
tures. Their patient had a significant response to treatment 
with anticholinesterase inhibitors and steroids, as did our pa-
tient (8). Our patient, however, had one other rare condition: 
adenocarcinoma of the bladder. LEMS is thought to have a 
paraneoplastic origin from small-cell carcinoma of the lung. 
Some rare case reports have chronicled the relationship be-
tween this condition and malignancies in the bladder, espe-
cially transitional cell carcinoma (4). Coexistence of MG 
and LEMS is very rare, but this presentation in our patient, 
who had a history of adenocarcinoma of the bladder, has not 
been previously reported.
CONCLUSION
Patients with LEMS should be evaluated very carefully for 
underlying malignancies. In most cases, the underlying ma-
lignancy is in the lung, but an extra-pulmonary origin, such 
as in the urinary system, is possible. Moreover, in cases of 
overlap syndrome, treatment of MG may improve the gener-
al condition of the patient.
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